25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ADC Therapeutics SA
Buy, Hold or Sell?

Let's analyze ADC Therapeutics SA together

I guess you are interested in ADC Therapeutics SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of ADC Therapeutics SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about ADC Therapeutics SA

I send you an email if I find something interesting about ADC Therapeutics SA.

1. Quick Overview

1.1. Quick analysis of ADC Therapeutics SA (30 sec.)










1.2. What can you expect buying and holding a share of ADC Therapeutics SA? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
4.0%

What is your share worth?

Current worth
$-1.64
Expected worth in 1 year
$-2.72
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-1.08
Return On Investment
-61.7%

For what price can you sell your share?

Current Price per Share
$1.75
Expected price per share
$1.18 - $1.86
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of ADC Therapeutics SA (5 min.)




Live pricePrice per Share (EOD)
$1.75
Intrinsic Value Per Share
$7.16 - $9.27
Total Value Per Share
$5.52 - $7.63

2.2. Growth of ADC Therapeutics SA (5 min.)




Is ADC Therapeutics SA growing?

Current yearPrevious yearGrowGrow %
How rich?-$171.9m$15.9m-$177.4m-109.8%

How much money is ADC Therapeutics SA making?

Current yearPrevious yearGrowGrow %
Making money-$53m-$44.6m-$8.4m-15.9%
Net Profit Margin-304.6%-230.4%--

How much money comes from the company's main activities?

2.3. Financial Health of ADC Therapeutics SA (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#923 / 933

Most Revenue
#253 / 933

Most Profit
#822 / 933

Most Efficient
#563 / 933
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of ADC Therapeutics SA?

Welcome investor! ADC Therapeutics SA's management wants to use your money to grow the business. In return you get a share of ADC Therapeutics SA.

First you should know what it really means to hold a share of ADC Therapeutics SA. And how you can make/lose money.

Speculation

The Price per Share of ADC Therapeutics SA is $1.75. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of ADC Therapeutics SA.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in ADC Therapeutics SA, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.64. Based on the TTM, the Book Value Change Per Share is $-0.27 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.41 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of ADC Therapeutics SA.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.42-24.0%-0.54-30.8%-0.43-24.8%-0.55-31.3%-0.54-30.6%
Usd Book Value Change Per Share-0.28-15.9%-0.27-15.4%-0.41-23.5%-0.14-8.0%-0.07-3.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.28-15.9%-0.27-15.4%-0.41-23.5%-0.14-8.0%-0.07-3.7%
Usd Price Per Share3.15-3.12-2.21-12.83-10.27-
Price to Earnings Ratio-1.88--1.69--1.59--7.23--5.79-
Price-to-Total Gains Ratio-11.31--4.39--8.38--48.83--48.83-
Price to Book Ratio-1.92--1.89--4.15-3.99-3.19-
Price-to-Total Gains Ratio-11.31--4.39--8.38--48.83--48.83-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.75
Number of shares571
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.27-0.14
Usd Total Gains Per Share-0.27-0.14
Gains per Quarter (571 shares)-154.16-79.59
Gains per Year (571 shares)-616.66-318.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-617-6270-319-328
20-1233-12441-637-646
30-1850-18611-956-964
40-2467-24781-1274-1282
50-3083-30951-1593-1600
60-3700-37122-1912-1918
70-4317-43292-2230-2236
80-4933-49462-2549-2554
90-5550-55632-2867-2872
100-6167-61803-3186-3190

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.025.00.00.0%0.025.00.00.0%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%3.015.02.015.0%5.016.04.020.0%5.016.04.020.0%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%1.00.024.04.0%1.00.024.04.0%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%3.015.02.015.0%5.016.04.020.0%5.016.04.020.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of ADC Therapeutics SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.279-0.270-3%-0.411+48%-0.139-50%-0.066-76%
Book Value Per Share---1.640-1.6370%0.165-1097%0.995-265%1.094-250%
Current Ratio--4.9205.166-5%4.780+3%7.351-33%7.253-32%
Debt To Asset Ratio--1.4931.474+1%0.971+54%0.806+85%0.674+121%
Debt To Equity Ratio----0%4.094-100%1.804-100%1.479-100%
Dividend Per Share----0%0.001-100%0.000-100%0.000-100%
Enterprise Value--83445362.55071933134.638+16%60487748.800+38%1359591248.764-94%1359591248.764-94%
Eps---0.419-0.540+29%-0.433+3%-0.548+31%-0.535+28%
Ev To Ebitda Ratio---0.702-0.629-10%-1.477+110%-7.203+926%-7.203+926%
Ev To Sales Ratio--1.1580.993+17%0.051+2156%infnan%infnan%
Free Cash Flow Per Share---0.241-0.344+43%-0.364+51%-0.417+73%-0.446+85%
Free Cash Flow To Equity Per Share---0.249-0.090-64%-0.183-26%0.065-481%0.002-12356%
Gross Profit Margin--1.1151.1200%1.318-15%1.221-9%1.176-5%
Intrinsic Value_10Y_max--9.268--------
Intrinsic Value_10Y_min--7.160--------
Intrinsic Value_1Y_max---1.113--------
Intrinsic Value_1Y_min---1.095--------
Intrinsic Value_3Y_max---1.789--------
Intrinsic Value_3Y_min---1.739--------
Intrinsic Value_5Y_max---0.588--------
Intrinsic Value_5Y_min---0.680--------
Market Cap169206800.000-95%330198362.550307594634.638+7%213611498.800+55%1242229473.888-73%993783579.110-67%
Net Profit Margin---2.441-3.046+25%-2.304-6%-2.699+11%-11.764+382%
Operating Margin---1.693-1.639-3%-1.812+7%-2.302+36%-7.245+328%
Operating Ratio--2.9992.977+1%2.878+4%3.159-5%13.156-77%
Pb Ratio-1.067+44%-1.920-1.889-2%-4.154+116%3.989-148%3.192-160%
Pe Ratio-1.043+44%-1.877-1.692-10%-1.592-15%-7.234+285%-5.787+208%
Price Per Share1.750-80%3.1503.115+1%2.209+43%12.834-75%10.267-69%
Price To Free Cash Flow Ratio-1.816+44%-3.268-2.330-29%-1.689-48%-3.429+5%-2.744-16%
Price To Total Gains Ratio-6.283+44%-11.309-4.386-61%-8.383-26%-48.828+332%-48.828+332%
Quick Ratio--4.4084.647-5%4.265+3%6.943-37%6.900-36%
Return On Assets---0.126-0.154+22%-0.092-27%-0.126+0%-0.161+28%
Return On Equity----0%-0.4620%-0.2730%-0.2890%
Total Gains Per Share---0.279-0.270-3%-0.410+47%-0.139-50%-0.066-76%
Usd Book Value---171946000.000-161578500.000-6%15910500.000-1181%95536500.000-280%105214000.000-263%
Usd Book Value Change Per Share---0.279-0.270-3%-0.411+48%-0.139-50%-0.066-76%
Usd Book Value Per Share---1.640-1.6370%0.165-1097%0.995-265%1.094-250%
Usd Dividend Per Share----0%0.001-100%0.000-100%0.000-100%
Usd Enterprise Value--83445362.55071933134.638+16%60487748.800+38%1359591248.764-94%1359591248.764-94%
Usd Eps---0.419-0.540+29%-0.433+3%-0.548+31%-0.535+28%
Usd Free Cash Flow---25259000.000-33722258.750+34%-35179000.000+39%-40381201.750+60%-43209961.400+71%
Usd Free Cash Flow Per Share---0.241-0.344+43%-0.364+51%-0.417+73%-0.446+85%
Usd Free Cash Flow To Equity Per Share---0.249-0.090-64%-0.183-26%0.065-481%0.002-12356%
Usd Market Cap169206800.000-95%330198362.550307594634.638+7%213611498.800+55%1242229473.888-73%993783579.110-67%
Usd Price Per Share1.750-80%3.1503.115+1%2.209+43%12.834-75%10.267-69%
Usd Profit---43969000.000-53037500.000+21%-44626750.000+1%-51695050.000+18%-50701160.000+15%
Usd Revenue--18016000.00017567250.000+3%30641500.000-41%20938100.000-14%16933860.000+6%
Usd Total Gains Per Share---0.279-0.270-3%-0.410+47%-0.139-50%-0.066-76%
 EOD+2 -6MRQTTM+18 -18YOY+23 -165Y+15 -2310Y+17 -21

3.3 Fundamental Score

Let's check the fundamental score of ADC Therapeutics SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.043
Price to Book Ratio (EOD)Between0-1-1.067
Net Profit Margin (MRQ)Greater than0-2.441
Operating Margin (MRQ)Greater than0-1.693
Quick Ratio (MRQ)Greater than14.408
Current Ratio (MRQ)Greater than14.920
Debt to Asset Ratio (MRQ)Less than11.493
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.126
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of ADC Therapeutics SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.568
Ma 20Greater thanMa 501.945
Ma 50Greater thanMa 1002.263
Ma 100Greater thanMa 2002.642
OpenGreater thanClose1.780
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About ADC Therapeutics SA

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Fundamental data was last updated by Penke on 2024-12-28 14:10:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit ADC Therapeutics SA earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare ADC Therapeutics SA to the Biotechnology industry mean.
  • A Net Profit Margin of -244.1% means that $-2.44 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of ADC Therapeutics SA:

  • The MRQ is -244.1%. The company is making a huge loss. -2
  • The TTM is -304.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-244.1%TTM-304.6%+60.6%
TTM-304.6%YOY-230.4%-74.2%
TTM-304.6%5Y-269.9%-34.7%
5Y-269.9%10Y-1,176.4%+906.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-244.1%-104.6%-139.5%
TTM-304.6%-216.4%-88.2%
YOY-230.4%-208.6%-21.8%
5Y-269.9%-353.9%+84.0%
10Y-1,176.4%-488.0%-688.4%
4.3.1.2. Return on Assets

Shows how efficient ADC Therapeutics SA is using its assets to generate profit.

  • Above 5% is considered healthy but always compare ADC Therapeutics SA to the Biotechnology industry mean.
  • -12.6% Return on Assets means that ADC Therapeutics SA generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of ADC Therapeutics SA:

  • The MRQ is -12.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.6%TTM-15.4%+2.8%
TTM-15.4%YOY-9.2%-6.2%
TTM-15.4%5Y-12.6%-2.8%
5Y-12.6%10Y-16.1%+3.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.6%-12.7%+0.1%
TTM-15.4%-13.0%-2.4%
YOY-9.2%-12.3%+3.1%
5Y-12.6%-13.7%+1.1%
10Y-16.1%-15.7%-0.4%
4.3.1.3. Return on Equity

Shows how efficient ADC Therapeutics SA is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare ADC Therapeutics SA to the Biotechnology industry mean.
  • 0.0% Return on Equity means ADC Therapeutics SA generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of ADC Therapeutics SA:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-46.2%+46.2%
TTM-5Y-27.3%+27.3%
5Y-27.3%10Y-28.9%+1.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.8%+16.8%
TTM--17.8%+17.8%
YOY-46.2%-16.4%-29.8%
5Y-27.3%-20.6%-6.7%
10Y-28.9%-21.2%-7.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of ADC Therapeutics SA.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient ADC Therapeutics SA is operating .

  • Measures how much profit ADC Therapeutics SA makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare ADC Therapeutics SA to the Biotechnology industry mean.
  • An Operating Margin of -169.3% means the company generated $-1.69  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of ADC Therapeutics SA:

  • The MRQ is -169.3%. The company is operating very inefficient. -2
  • The TTM is -163.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-169.3%TTM-163.9%-5.4%
TTM-163.9%YOY-181.2%+17.3%
TTM-163.9%5Y-230.2%+66.3%
5Y-230.2%10Y-724.5%+494.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-169.3%-193.6%+24.3%
TTM-163.9%-321.1%+157.2%
YOY-181.2%-227.9%+46.7%
5Y-230.2%-373.0%+142.8%
10Y-724.5%-506.1%-218.4%
4.3.2.2. Operating Ratio

Measures how efficient ADC Therapeutics SA is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.00 means that the operating costs are $3.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of ADC Therapeutics SA:

  • The MRQ is 2.999. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.977. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.999TTM2.977+0.021
TTM2.977YOY2.878+0.099
TTM2.9775Y3.159-0.182
5Y3.15910Y13.156-9.997
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9992.171+0.828
TTM2.9773.250-0.273
YOY2.8783.231-0.353
5Y3.1594.838-1.679
10Y13.1566.440+6.716
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of ADC Therapeutics SA.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if ADC Therapeutics SA is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.92 means the company has $4.92 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of ADC Therapeutics SA:

  • The MRQ is 4.920. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.166. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.920TTM5.166-0.246
TTM5.166YOY4.780+0.386
TTM5.1665Y7.351-2.185
5Y7.35110Y7.253+0.098
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9203.610+1.310
TTM5.1663.850+1.316
YOY4.7804.605+0.175
5Y7.3515.895+1.456
10Y7.2536.178+1.075
4.4.3.2. Quick Ratio

Measures if ADC Therapeutics SA is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare ADC Therapeutics SA to the Biotechnology industry mean.
  • A Quick Ratio of 4.41 means the company can pay off $4.41 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of ADC Therapeutics SA:

  • The MRQ is 4.408. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.647. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.408TTM4.647-0.240
TTM4.647YOY4.265+0.382
TTM4.6475Y6.943-2.295
5Y6.94310Y6.900+0.042
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.4083.034+1.374
TTM4.6473.355+1.292
YOY4.2654.297-0.032
5Y6.9435.890+1.053
10Y6.9006.434+0.466
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of ADC Therapeutics SA.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of ADC Therapeutics SA assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare ADC Therapeutics SA to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.49 means that ADC Therapeutics SA assets are financed with 149.3% credit (debt) and the remaining percentage (100% - 149.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of ADC Therapeutics SA:

  • The MRQ is 1.493. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.474. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.493TTM1.474+0.019
TTM1.474YOY0.971+0.503
TTM1.4745Y0.806+0.668
5Y0.80610Y0.674+0.131
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4930.341+1.152
TTM1.4740.343+1.131
YOY0.9710.310+0.661
5Y0.8060.366+0.440
10Y0.6740.385+0.289
4.5.4.2. Debt to Equity Ratio

Measures if ADC Therapeutics SA is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare ADC Therapeutics SA to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of ADC Therapeutics SA:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY4.094-4.094
TTM-5Y1.804-1.804
5Y1.80410Y1.479+0.326
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.393-0.393
TTM-0.429-0.429
YOY4.0940.382+3.712
5Y1.8040.439+1.365
10Y1.4790.489+0.990
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings ADC Therapeutics SA generates.

  • Above 15 is considered overpriced but always compare ADC Therapeutics SA to the Biotechnology industry mean.
  • A PE ratio of -1.88 means the investor is paying $-1.88 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of ADC Therapeutics SA:

  • The EOD is -1.043. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.877. Based on the earnings, the company is expensive. -2
  • The TTM is -1.692. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.043MRQ-1.877+0.834
MRQ-1.877TTM-1.692-0.185
TTM-1.692YOY-1.592-0.100
TTM-1.6925Y-7.234+5.542
5Y-7.23410Y-5.787-1.447
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.043-2.247+1.204
MRQ-1.877-2.693+0.816
TTM-1.692-3.214+1.522
YOY-1.592-3.335+1.743
5Y-7.234-6.368-0.866
10Y-5.787-6.692+0.905
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of ADC Therapeutics SA:

  • The EOD is -1.816. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.268. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.330. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.816MRQ-3.268+1.453
MRQ-3.268TTM-2.330-0.938
TTM-2.330YOY-1.689-0.641
TTM-2.3305Y-3.429+1.100
5Y-3.42910Y-2.744-0.686
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.816-2.993+1.177
MRQ-3.268-3.671+0.403
TTM-2.330-4.037+1.707
YOY-1.689-4.482+2.793
5Y-3.429-8.190+4.761
10Y-2.744-9.383+6.639
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of ADC Therapeutics SA is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -1.92 means the investor is paying $-1.92 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of ADC Therapeutics SA:

  • The EOD is -1.067. Based on the equity, the company is expensive. -2
  • The MRQ is -1.920. Based on the equity, the company is expensive. -2
  • The TTM is -1.889. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.067MRQ-1.920+0.853
MRQ-1.920TTM-1.889-0.031
TTM-1.889YOY-4.154+2.265
TTM-1.8895Y3.989-5.878
5Y3.98910Y3.192+0.798
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.0671.933-3.000
MRQ-1.9202.265-4.185
TTM-1.8892.447-4.336
YOY-4.1542.454-6.608
5Y3.9893.664+0.325
10Y3.1924.239-1.047
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of ADC Therapeutics SA.

4.8.1. Institutions holding ADC Therapeutics SA

Institutions are holding 61.6% of the shares of ADC Therapeutics SA.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Redmile Group, LLC16.20572.9078156692174000002.6196
2024-09-30Prosight Management, LP9.96627.46989636237662370.6921
2024-09-30Orbimed Advisors, LLC4.6890.259545338012169775.0263
2024-06-30BlackRock Inc3.67640.0003355474235547420
2024-09-30Morgan Stanley - Brokerage Accounts3.14490.00073040794-2889664-48.7258
2024-09-30Bank of America Corp2.58350.000724979401281522105.3521
2024-09-30SILVERARC CAPITAL MANAGEMENT, LLC1.85651.26981795080263101.4875
2024-09-30Goldman Sachs Group Inc1.74640.0009168859416387710.748
2024-09-30Junked Platinum Investment Management Ltd1.4940.206144451614836311.4464
2024-09-30State Street Corp1.14390.0001110601111471511.5722
2024-09-30Geode Capital Management, LLC0.98580.000295317112845415.5755
2024-09-30Vantage Consulting Group Inc.0.879923.473685073700
2024-09-30Blue Owl Capital Holdings LP0.75870.445773356800
2024-09-30Millennium Management LLC0.73680.0011712401-104055-12.7447
2024-09-30Vanguard Group Inc0.5578053935913513033.4291
2024-09-30Northern Trust Corp0.49750.00034810374580231990.1929
2024-09-30GCM Grosvenor Holdings, LLC0.4250.196741088800
2024-09-30D. E. Shaw & Co LP0.2940.0008284243205317.7854
2024-09-30Two Sigma Investments LLC0.25360.0017245253-83511-25.4015
2024-09-30Sphera Funds Management Ltd.0.21210.1028205036-480511-70.0916
Total 52.107736.338550382625+3157140+6.3%

4.9.2. Funds holding ADC Therapeutics SA

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-11-30iShares Russell 2000 ETF2.24360.0064216934700
2024-08-31Biotech Growth Ord1.62570.9711157190000
2024-09-30Fidelity Small Cap Index0.85540.009582707011122015.5368
2024-11-30iShares Russell 2000 Growth ETF0.45190.007943697200
2024-11-30State St Russell Sm/Mid Cp® Indx NL Cl C0.4150.001940123900
2024-11-30Vanguard Russell 2000 ETF0.39240.0066379397100642.7249
2024-11-30iShares Russell 2000 Value ETF0.32280.005431214600
2024-11-30State St Russell Sm Cap® Indx SL Cl I0.31620.007130570000
2024-09-30NT R2000 Index Fund - NL0.2040.00941972751972750
2024-11-30Schwab Small Cap Index0.20090.006719425800
2024-11-30iShares Micro-Cap ETF0.1920.044718560000
2024-09-30NT R2000 Index Fund - DC - NL - 20.16340.00941579661579660
2024-09-30US SMID CAP EQ INDEX0.15310.00431480423474830.6706
2024-11-30iShares Russell 2000 Small-Cap Idx Instl0.14440.006713959600
2024-09-30Russell 2000 Index Non-Lendable Fund E0.1360.0095131467-4334-3.1914
2024-11-30SPDR® Russell 2000 US Small Cap ETF0.11060.00551069512227826.3106
2024-09-30NT R2000 Growth Index Fund - L0.10810.01131044851044850
2024-09-30Northern Trust Russell 2000 Growth Index0.10810.01131044851044850
2024-10-31Nuveen Small Cap Blend Idx R60.09820.00769493800
2024-10-31EQ/2000 Managed Volatility IB0.0980.00779475100
Total 8.33981.158063585+738187+9.2%

5.3. Insider Transactions

Insiders are holding 20.642% of the shares of ADC Therapeutics SA.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-12-11Redmile Group, LlcBUY1000003.04
2024-12-04Redmile Group, LlcSELL253522.07
2024-07-01Redmile Group, LlcBUY4000002.81
2024-06-17Robert AzelbySELL69952.89
2024-05-07Ameet MallikSELL297314.48
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Net Debt  -186,87832,657-154,22144,264-109,957-65,765-175,722232,95857,236



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets349,079
Total Liabilities521,025
Total Stockholder Equity-171,946
 As reported
Total Liabilities 521,025
Total Stockholder Equity+ -171,946
Total Assets = 349,079

Assets

Total Assets349,079
Total Current Assets333,005
Long-term Assets16,074
Total Current Assets
Cash And Cash Equivalents 274,272
Net Receivables 24,030
Inventory 16,072
Other Current Assets 18,631
Total Current Assets  (as reported)333,005
Total Current Assets  (calculated)333,005
+/-0
Long-term Assets
Property Plant Equipment 14,909
Long-term Assets Other 1,165
Long-term Assets  (as reported)16,074
Long-term Assets  (calculated)16,074
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities67,679
Long-term Liabilities453,346
Total Stockholder Equity-171,946
Total Current Liabilities
Accounts payable 14,372
Other Current Liabilities 53,307
Total Current Liabilities  (as reported)67,679
Total Current Liabilities  (calculated)67,679
+/-0
Long-term Liabilities
Long term Debt 114,189
Capital Lease Obligations Min Short Term Debt10,362
Long-term Liabilities Other 7,649
Long-term Liabilities  (as reported)453,346
Long-term Liabilities  (calculated)132,200
+/- 321,146
Total Stockholder Equity
Common Stock8,233
Retained Earnings -1,462,591
Accumulated Other Comprehensive Income 203
Other Stockholders Equity 1,282,209
Total Stockholder Equity (as reported)-171,946
Total Stockholder Equity (calculated)-171,946
+/-0
Other
Capital Stock8,233
Cash and Short Term Investments 274,272
Common Stock Shares Outstanding 104,825
Liabilities and Stockholders Equity 349,079
Net Debt 57,236
Net Invested Capital -57,757
Net Working Capital 265,326
Property Plant and Equipment Gross 20,142
Short Long Term Debt Total 331,508



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-03-31
> Total Assets 
150,558
150,558
150,558
200,839
200,839
137,682
137,682
373,842
373,842
521,526
513,692
461,705
464,386
637,979
617,972
581,886
520,463
531,759
529,168
467,672
507,302
466,900
354,782
307,966
371,779
349,079
349,079371,779307,966354,782466,900507,302467,672529,168531,759520,463581,886617,972637,979464,386461,705513,692521,526373,842373,842137,682137,682200,839200,839150,558150,558150,558
   > Total Current Assets 
0
142,080
142,080
185,396
185,396
122,606
122,606
359,125
359,125
506,419
450,450
393,242
394,432
568,408
525,182
487,710
424,442
438,099
446,015
380,007
412,808
375,598
336,291
290,206
355,359
333,005
333,005355,359290,206336,291375,598412,808380,007446,015438,099424,442487,710525,182568,408394,432393,242450,450506,419359,125359,125122,606122,606185,396185,396142,080142,0800
       Cash And Cash Equivalents 
0
138,807
138,807
182,156
182,156
115,551
115,551
348,593
348,593
494,416
439,195
383,122
371,884
530,194
466,544
430,874
376,778
380,860
326,441
310,547
347,510
310,407
278,598
234,285
300,119
274,272
274,272300,119234,285278,598310,407347,510310,547326,441380,860376,778430,874466,544530,194371,884383,122439,195494,416348,593348,593115,551115,551182,156182,156138,807138,8070
       Net Receivables 
0
1,889
1,889
3
3
2,840
2,840
0
0
0
3,100
0
2,079
15,896
30,218
26,752
20,863
23,251
77,714
24,037
23,866
21,180
25,182
23,186
22,868
24,030
24,03022,86823,18625,18221,18023,86624,03777,71423,25120,86326,75230,21815,8962,07903,1000002,8402,840331,8891,8890
       Other Current Assets 
0
180
180
3,237
3,237
1,743
1,743
10,532
10,532
12,003
1,656
10,120
12,751
14,310
17,298
18,246
12,151
18,243
28,039
27,173
22,004
21,283
16,334
16,738
17,181
18,631
18,63117,18116,73816,33421,28322,00427,17328,03918,24312,15118,24617,29814,31012,75110,1201,65612,00310,53210,5321,7431,7433,2373,2371801800
   > Long-term Assets 
0
8,478
8,478
15,443
15,443
15,076
15,076
14,717
14,717
15,107
63,242
68,463
69,954
69,571
92,790
94,176
96,021
93,660
83,153
87,665
94,494
91,302
18,491
17,760
16,420
16,074
16,07416,42017,76018,49191,30294,49487,66583,15393,66096,02194,17692,79069,57169,95468,46363,24215,10714,71714,71715,07615,07615,44315,4438,4788,4780
       Property Plant Equipment 
0
1,540
1,540
6,760
6,760
6,274
6,274
5,508
5,508
4,904
4,758
10,543
11,338
11,562
11,230
10,664
9,690
9,877
9,981
15,708
16,371
15,532
16,133
15,844
15,168
14,909
14,90915,16815,84416,13315,53216,37115,7089,9819,8779,69010,66411,23011,56211,33810,5434,7584,9045,5085,5086,2746,2746,7606,7601,5401,5400
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
47,908
47,381
46,212
44,002
41,236
38,734
36,817
34,687
31,152
29,533
28,322
26,989
1,647
930
260
0
02609301,64726,98928,32229,53331,15234,68736,81738,73441,23644,00246,21247,38147,9080000000000
       Intangible Assets 
0
6,674
6,674
8,419
8,419
8,434
8,434
187,477
187,477
0
10,179
0
12,010
13,316
13,582
13,851
14,575
14,598
14,360
13,586
13,536
12,358
0
0
0
0
000012,35813,53613,58614,36014,59814,57513,85113,58213,31612,010010,1790187,477187,4778,4348,4348,4198,4196,6746,6740
       Other Assets 
0
0
264
264
368
368
0
384
389
0
397
392
394
1,617
27,373
31,640
35,833
35,452
28,614
0
0
37,319
0
0
0
0
000037,3190028,61435,45235,83331,64027,3731,6173943923970389384036836826426400
> Total Liabilities 
24,315
24,315
24,315
22,850
22,850
26,526
26,526
177,540
177,540
145,467
178,187
163,737
220,468
450,671
451,884
419,219
405,117
426,976
440,441
429,987
515,891
521,081
503,031
502,415
503,449
521,025
521,025503,449502,415503,031521,081515,891429,987440,441426,976405,117419,219451,884450,671220,468163,737178,187145,467177,540177,54026,52626,52622,85022,85024,31524,31524,315
   > Total Current Liabilities 
0
22,354
22,354
17,005
17,005
19,943
19,943
31,368
31,368
32,563
40,436
41,398
51,499
59,300
73,935
70,774
73,684
87,573
98,957
81,086
80,581
78,206
67,670
62,985
57,632
67,679
67,67957,63262,98567,67078,20680,58181,08698,95787,57373,68470,77473,93559,30051,49941,39840,43632,56331,36831,36819,94319,94317,00517,00522,35422,3540
       Short-term Debt 
0
0
0
1,087
1,087
1,132
1,132
4,212
4,212
3,693
4,633
4,427
7,181
7,587
7,604
7,530
7,482
13,304
13,571
14,980
15,493
15,746
2,934
1,432
1,415
0
01,4151,4322,93415,74615,49314,98013,57113,3047,4827,5307,6047,5877,1814,4274,6333,6934,2124,2121,1321,1321,0871,087000
       Short Long Term Debt 
0
0
0
0
0
0
0
3,113
2,642
0
3,631
3,594
6,193
6,575
6,575
6,549
6,573
12,469
12,474
13,533
13,861
14,329
0
0
0
0
000014,32913,86113,53312,47412,4696,5736,5496,5756,5756,1933,5943,63102,6423,1130000000
       Accounts payable 
0
6,750
6,750
1,166
1,166
3,329
3,329
6,797
6,797
6,146
5,279
11,462
14,631
12,028
12,080
16,453
13,019
11,611
12,351
8,694
11,691
8,977
15,569
14,315
10,708
14,372
14,37210,70814,31515,5698,97711,6918,69412,35111,61113,01916,45312,08012,02814,63111,4625,2796,1466,7976,7973,3293,3291,1661,1666,7506,7500
       Other Current Liabilities 
0
13,839
13,839
14,752
14,752
15,482
15,482
-148
22,633
22,633
30,375
25,272
29,450
39,685
50,497
46,791
53,183
62,658
73,035
57,412
53,397
53,483
49,167
47,238
45,509
53,307
53,30745,50947,23849,16753,48353,39757,41273,03562,65853,18346,79150,49739,68529,45025,27230,37522,63322,633-14815,48215,48214,75214,75213,83913,8390
   > Long-term Liabilities 
0
1,961
1,961
5,845
5,845
6,583
6,583
146,172
146,172
112,904
137,751
122,339
168,969
391,371
377,949
348,445
331,433
339,403
341,484
348,901
435,310
442,875
435,361
439,430
445,817
453,346
453,346445,817439,430435,361442,875435,310348,901341,484339,403331,433348,445377,949391,371168,969122,339137,751112,904146,172146,1726,5836,5835,8455,8451,9611,9610
       Other Liabilities 
0
0
1,556
1,556
2,684
2,684
0
109,983
76,511
0
100,511
78,967
76,709
83,682
65,138
49,312
31,176
27,832
25,327
0
0
29,826
0
0
0
0
000029,8260025,32727,83231,17649,31265,13883,68276,70978,967100,511076,511109,98302,6842,6841,5561,55600
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
926
631
713
894
954
954
0
916
896
0
0
0
0
000089691609549548947136319260000000000000
> Total Stockholder Equity
126,243
126,243
126,243
177,989
177,989
111,156
111,156
196,302
196,302
376,059
335,505
297,968
243,918
187,308
166,088
162,667
115,346
104,783
88,727
37,685
-8,589
-54,181
-148,249
-194,449
-131,670
-171,946
-171,946-131,670-194,449-148,249-54,181-8,58937,68588,727104,783115,346162,667166,088187,308243,918297,968335,505376,059196,302196,302111,156111,156177,989177,989126,243126,243126,243
   Common Stock
0
401
401
424
424
4,361
4,361
5,795
5,795
6,314
6,314
6,314
6,445
6,445
6,445
6,445
6,445
6,699
7,312
7,312
7,312
7,312
7,312
7,312
8,233
8,233
8,2338,2337,3127,3127,3127,3127,3127,3126,6996,4456,4456,4456,4456,4456,3146,3146,3145,7955,7954,3614,3614244244014010
   Retained Earnings Total Equity00000000000000000000000000
   Accumulated Other Comprehensive Income 
0
5,659
5,659
5,784
5,784
5,542
5,542
16,508
16,508
27,647
42,998
56,985
75,272
89,930
102,829
116,069
133,122
147,203
155,327
163,286
164,129
165,995
-93
-201
-338
203
203-338-201-93165,995164,129163,286155,327147,203133,122116,069102,82989,93075,27256,98542,99827,64716,50816,5085,5425,5425,7845,7845,6595,6590
   Capital Surplus 
0
0
0
527,083
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000527,083000
   Treasury Stock00000000000000000000000000
   Other Stockholders Equity 
0
452,268
452,268
553,724
553,724
549,822
549,822
792,601
792,601
981,028
981,052
981,055
981,156
981,437
981,699
981,699
981,699
1,007,409
1,006,773
1,007,198
1,007,198
1,007,547
1,180,004
1,180,518
1,279,057
1,282,209
1,282,2091,279,0571,180,5181,180,0041,007,5471,007,1981,007,1981,006,7731,007,409981,699981,699981,699981,437981,156981,055981,052981,028792,601792,601549,822549,822553,724553,724452,268452,2680



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue69,558
Cost of Revenue-2,529
Gross Profit67,02967,029
 
Operating Income (+$)
Gross Profit67,029
Operating Expense-233,015
Operating Income-165,986-165,986
 
Operating Expense (+$)
Research Development127,127
Selling General Administrative48,424
Selling And Marketing Expenses57,464
Operating Expense233,015233,015
 
Net Interest Income (+$)
Interest Income6,623
Interest Expense-46,325
Other Finance Cost-125
Net Interest Income-39,577
 
Pretax Income (+$)
Operating Income-165,986
Net Interest Income-39,577
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-195,419-136,553
EBIT - interestExpense = -196,354
-200,947
-193,728
Interest Expense46,325
Earnings Before Interest and Taxes (EBIT)-150,029-149,094
Earnings Before Interest and Taxes (EBITDA)-146,762
 
After tax Income (+$)
Income Before Tax-195,419
Tax Provision--2,991
Net Income From Continuing Ops-178,507-192,428
Net Income-240,053
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses235,544
Total Other Income/Expenses Net-29,43339,577
 

Technical Analysis of ADC Therapeutics SA
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of ADC Therapeutics SA. The general trend of ADC Therapeutics SA is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine ADC Therapeutics SA's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of ADC Therapeutics SA.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.8 < 1.8 < 1.86.

The bearish price targets are: 1.71 > 1.4501 > 1.18.

Tweet this
ADC Therapeutics SA Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of ADC Therapeutics SA. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

ADC Therapeutics SA Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of ADC Therapeutics SA. The current macd is -0.14610872.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the ADC Therapeutics SA price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for ADC Therapeutics SA. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the ADC Therapeutics SA price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
ADC Therapeutics SA Daily Moving Average Convergence/Divergence (MACD) ChartADC Therapeutics SA Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of ADC Therapeutics SA. The current adx is 11.64.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell ADC Therapeutics SA shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
ADC Therapeutics SA Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of ADC Therapeutics SA. The current sar is 2.3818551.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
ADC Therapeutics SA Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of ADC Therapeutics SA. The current rsi is 40.57. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
ADC Therapeutics SA Daily Relative Strength Index (RSI) ChartADC Therapeutics SA Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of ADC Therapeutics SA. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the ADC Therapeutics SA price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
ADC Therapeutics SA Daily Stochastic Oscillator ChartADC Therapeutics SA Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of ADC Therapeutics SA. The current cci is -141.27914744.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
ADC Therapeutics SA Daily Commodity Channel Index (CCI) ChartADC Therapeutics SA Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of ADC Therapeutics SA. The current cmo is -24.36251025.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
ADC Therapeutics SA Daily Chande Momentum Oscillator (CMO) ChartADC Therapeutics SA Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of ADC Therapeutics SA. The current willr is -85.57692308.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
ADC Therapeutics SA Daily Williams %R ChartADC Therapeutics SA Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of ADC Therapeutics SA.

ADC Therapeutics SA Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of ADC Therapeutics SA. The current atr is 0.20320323.

ADC Therapeutics SA Daily Average True Range (ATR) ChartADC Therapeutics SA Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of ADC Therapeutics SA. The current obv is 5,451,347.

ADC Therapeutics SA Daily On-Balance Volume (OBV) ChartADC Therapeutics SA Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of ADC Therapeutics SA. The current mfi is 39.13.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
ADC Therapeutics SA Daily Money Flow Index (MFI) ChartADC Therapeutics SA Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for ADC Therapeutics SA.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-08-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-20MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-23STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-07BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-14BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-15ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-11-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-01-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

ADC Therapeutics SA Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of ADC Therapeutics SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.568
Ma 20Greater thanMa 501.945
Ma 50Greater thanMa 1002.263
Ma 100Greater thanMa 2002.642
OpenGreater thanClose1.780
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of ADC Therapeutics SA with someone you think should read this too:
  • Are you bullish or bearish on ADC Therapeutics SA? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about ADC Therapeutics SA? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about ADC Therapeutics SA

I send you an email if I find something interesting about ADC Therapeutics SA.


Comments

How you think about this?

Leave a comment

Stay informed about ADC Therapeutics SA.

Receive notifications about ADC Therapeutics SA in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.